Organ Transplantation Research Today is a free monthly online journal that collates and summarizes the latest research about Organ Transplantation, including details on risks, prognosis, procedure, surgery.

Volume 2 (2005), Issue 5 (May)

1. Oxidative stress in organ preservation: a multifaceted approach to cardioplegia.
   Biomed Pharmacother, 59(4): 149-57. [Abstract] [Full-text]
2. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients.
   Am J Surg, 189(5): 552-7; discussion 557. [Abstract] [Full-text]
3. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation.
   J Am Coll Cardiol, 45(9): 1538-42. [Abstract] [Full-text]
4. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.
   J Am Coll Cardiol, 45(9): 1532-7. [Abstract] [Full-text]
5. Health insurance and cardiac transplantation: a call for reform.
   J Am Coll Cardiol, 45(9): 1388-91. [Abstract] [Full-text]
6. Impact of aberrant arterial anatomy and location of anastomosis on technical outcomes after liver transplantation.
   J Gastrointest Surg, 9(5): 672-8. [Abstract] [Full-text]
7. Ischaemic preconditioning in transplantation and major resection of the liver.
   Br J Surg, 92(5): 528-38. [Abstract] [Full-text]
8. Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators.
   J Thorac Cardiovasc Surg, 129(5): 1160-7. [Abstract] [Full-text]
9. Donor cause of death and medium-term survival after heart transplantation: a United Kingdom national study.
   J Thorac Cardiovasc Surg, 129(5): 1153-9. [Abstract] [Full-text]
10. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation.
    J Thorac Cardiovasc Surg, 129(5): 1144-52. [Abstract] [Full-text]
11. Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation.
    J Thorac Cardiovasc Surg, 129(5): 1137-43. [Abstract] [Full-text]
12. Laparoscopic organ retrieval for living donor liver transplantation does not prevent graft injury.
    Transplant Proc, 37(3): 1625-7. [Abstract] [Full-text]
13. Changes in quality of life after renal transplantation.
    Transplant Proc, 37(3): 1618-21. [Abstract] [Full-text]
14. Living donor kidney transplantation: impact of differentiated immunosuppressive regimen.
    Transplant Proc, 37(3): 1616-7. [Abstract] [Full-text]
15. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Transplant Proc, 37(3): 1612-5. [Abstract] [Full-text]
16. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    Transplant Proc, 37(3): 1608-11. [Abstract] [Full-text]
17. Relationship between donor factors, immunogenic up-regulation, and outcome after kidney transplantation.
    Transplant Proc, 37(3): 1605-7. [Abstract] [Full-text]
18. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
    Transplant Proc, 37(3): 1601-4. [Abstract] [Full-text]
19. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Transplant Proc, 37(3): 1597-600. [Abstract] [Full-text]
20. Valsartan-induced hematocrit changes in renal transplant patients.
    Transplant Proc, 37(3): 1586-8. [Abstract] [Full-text]
21. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Transplant Proc, 37(3): 1583-5. [Abstract] [Full-text]
22. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Transplant Proc, 37(3): 1580-2. [Abstract] [Full-text]
23. Impact of pregnancy on the function of transplanted kidneys.
    Transplant Proc, 37(3): 1577-9. [Abstract] [Full-text]
24. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
    Transplant Proc, 37(3): 1574-6. [Abstract] [Full-text]
25. Pediatric renal transplantation: 13 years of experience--report from the Chilean Cooperative Multicenter Group.
    Transplant Proc, 37(3): 1569-73. [Abstract] [Full-text]
26. ABO-incompatible liver transplantation: a new therapeutic option for patients with acute liver failure in Chile.
    Transplant Proc, 37(3): 1567-8. [Abstract] [Full-text]
27. Sirolimus improves renal function in cardiac transplantation.
    Transplant Proc, 37(3): 1546-7. [Abstract] [Full-text]
28. Myocardial preservation using Celsior: clinical results in high-risk cardiac transplantation.
    Transplant Proc, 37(3): 1543-5. [Abstract] [Full-text]
29. Respiratory disorders and quality of sleep in patients on the waiting list for lung transplantation.
    Transplant Proc, 37(3): 1537-9. [Abstract] [Full-text]
30. Long-term results of lung transplantation for emphysema.
    Transplant Proc, 37(3): 1530-3. [Abstract] [Full-text]
31. Pulmonary tailoring and lobar transplantation to overcome size disparities in lung transplantation.
    Transplant Proc, 37(3): 1526-9. [Abstract] [Full-text]
32. Analysis of lung transplant recipients surviving beyond 5 years.
    Transplant Proc, 37(3): 1523-5. [Abstract] [Full-text]
33. Pediatric lung transplantation.
    Transplant Proc, 37(3): 1519-22. [Abstract] [Full-text]
34. Circadian variability of blood pressure in liver transplant recipients without antihypertensive therapy.
    Transplant Proc, 37(3): 1515-6. [Abstract] [Full-text]
35. Mycotic pseudoaneurysms after liver transplantation.
    Transplant Proc, 37(3): 1512-4. [Abstract] [Full-text]
36. Mycophenolate mofetil-induced neutropenia in liver transplantation.
    Transplant Proc, 37(3): 1509-11. [Abstract] [Full-text]
37. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
    Transplant Proc, 37(3): 1507-8. [Abstract] [Full-text]
38. Liver transplantation at the Cuban Center for Medical and Surgical Research.
    Transplant Proc, 37(3): 1505-6. [Abstract] [Full-text]
39. Psychological adaptation of liver transplant recipients.
    Transplant Proc, 37(3): 1502-4. [Abstract] [Full-text]
40. Preoperative factors and models predicting mortality in liver transplantation.
    Transplant Proc, 37(3): 1499-501. [Abstract] [Full-text]
41. Lack of association of recipient MCP-1 gene promoter polymorphism with acute graft rejection after orthotopic liver transplantation.
    Transplant Proc, 37(3): 1496-8. [Abstract] [Full-text]
42. Doppler ultrasonography for the assessment of tumor necrosis after percutaneous ethanol injection prior to liver transplantation as adjuvant therapy of hepatocellular carcinoma.
    Transplant Proc, 37(3): 1493-5. [Abstract] [Full-text]
43. Results of liver transplantation in patients with previous portosystemic shunts.
    Transplant Proc, 37(3): 1491-2. [Abstract] [Full-text]
44. Liver transplant results for hepatocellular carcinoma applying strict preoperative selection criteria.
    Transplant Proc, 37(3): 1488-90. [Abstract] [Full-text]
45. Prevalence of hepatitis C virus genotypes in a Spanish liver transplant unit.
    Transplant Proc, 37(3): 1486-7. [Abstract] [Full-text]
46. Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation.
    Transplant Proc, 37(3): 1484-5. [Abstract] [Full-text]
47. Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis.
    Transplant Proc, 37(3): 1482-3. [Abstract] [Full-text]
48. Therapy of intractable pruritus with MARS.
    Transplant Proc, 37(3): 1480-1. [Abstract] [Full-text]
49. Prospective histopathological analysis of hepatocellular carcinoma treated with percutaneous ethanol injection in patients on the waiting list for liver transplantation.
    Transplant Proc, 37(3): 1477-9. [Abstract] [Full-text]
50. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant.
    Transplant Proc, 37(3): 1473-4. [Abstract] [Full-text]
51. Markers of fibrosis in early biopsies of renal transplants.
    Transplant Proc, 37(3): 1468-70. [Abstract] [Full-text]
52. Lumbar bone mineral density after kidney transplantation: a three-year prospective study.
    Transplant Proc, 37(3): 1466-7. [Abstract] [Full-text]
53. Cost of renal transplant maintenance immunosuppression: effect of control of vascular risk factors.
    Transplant Proc, 37(3): 1464-5. [Abstract] [Full-text]
54. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection.
    Transplant Proc, 37(3): 1462-3. [Abstract] [Full-text]
55. Effect of parathyroidectomy on renal graft function.
    Transplant Proc, 37(3): 1459-61. [Abstract] [Full-text]
56. Antibodies against the donor antigen glutathione S-transferase T1 after renal transplantation.
    Transplant Proc, 37(3): 1457-8. [Abstract] [Full-text]
57. Kidney-pancreas transplants: is it so difficult to start a program?
    Transplant Proc, 37(3): 1455-6. [Abstract] [Full-text]
58. High initial blood levels of tacrolimus in overweight renal transplant recipients.
    Transplant Proc, 37(3): 1453-4. [Abstract] [Full-text]
59. Psychologic stages in renal transplant.
    Transplant Proc, 37(3): 1449-52. [Abstract] [Full-text]
60. Minimal model analysis in nondiabetic renal transplant recipients with hepatitis C.
    Transplant Proc, 37(3): 1446-8. [Abstract] [Full-text]
61. Pancreas islet transplantation in patients with type 1 diabetes mellitus after kidney transplantation.
    Transplant Proc, 37(3): 1443-5. [Abstract] [Full-text]
62. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression.
    Transplant Proc, 37(3): 1441-2. [Abstract] [Full-text]
63. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
    Transplant Proc, 37(3): 1438-40. [Abstract] [Full-text]
64. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function.
    Transplant Proc, 37(3): 1435-7. [Abstract] [Full-text]
65. Change in serum creatinine levels between 6 and 12 months and kidney graft survival: influence of proteinuria.
    Transplant Proc, 37(3): 1433-4. [Abstract] [Full-text]
66. Similar impact of slow and delayed graft function on renal allograft outcome and function.
    Transplant Proc, 37(3): 1431-2. [Abstract] [Full-text]
67. Modulation factors of oxidative status in stable renal transplantation.
    Transplant Proc, 37(3): 1428-30. [Abstract] [Full-text]
68. Evaluation of renal grafts in patients with lupus nephritis as cause of end-stage renal disease.
    Transplant Proc, 37(3): 1426-7. [Abstract] [Full-text]
69. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant.
    Transplant Proc, 37(3): 1424-5. [Abstract] [Full-text]
70. Role of poly-(ADP-ribose) polymerase in transplant acute tubular necrosis and its relationship with delayed renal function.
    Transplant Proc, 37(3): 1421-3. [Abstract] [Full-text]
71. Wisconsin and Celsior solutions in renal preservation: a comparative preliminary study.
    Transplant Proc, 37(3): 1419-20. [Abstract] [Full-text]
72. Comparison of pituitary-ovarian function in patients who have undergone successful renal transplantation and healthy women.
    Fertil Steril, 83(5): 1553-6. [Abstract] [Full-text]
73. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.
    Lancet, 365(9470): 1570-6. [Abstract] [Full-text]
74. Looped silk tie: surgical technique for management of the renal vein during laparoscopic live-donor nephrectomy.
    J Endourol, 19(3): 401-5. [Abstract] [Full-text]
75. Accuracy of three-dimensional CT angiography for preoperative vascular evaluation of laparoscopic living renal donors.
    J Endourol, 19(3): 339-41. [Abstract] [Full-text]
76. Acute fatty liver of pregnancy -- an underlying condition for herpes simplex type 2 fulminant hepatitis necessitating liver transplantation.
    Z Gastroenterol, 43(5): 451-4. [Abstract] [Full-text]
77. Mechanism of atrial flutter occurring late after orthotopic heart transplantation with atrio-atrial anastomosis.
    Pacing Clin Electrophysiol, 28(5): 412-20. [Abstract] [Full-text]
78. Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome.
    Cancer Biother Radiopharm, 20(2): 209-14. [Abstract] [Full-text]
79. Detection of EBV-DNA in serum samples of an immunosuppressed child during a three years follow-up: association of clinical and PCR data with active infection.
    Rev Inst Med Trop Sao Paulo, 47(2): 99-102. [Abstract] [Full-text]
80. Deep brain stimulation in a patient on immunosuppressive therapy after renal transplant.
    Parkinsonism Relat Disord, 11(4): 259-60. [Abstract] [Full-text]
81. Knot in the cava--an unusual complication of swan-ganz catheters.
    Eur J Vasc Endovasc Surg, 29(6): 651-3. [Abstract] [Full-text]
82. Bioactivation of an anorganic bone matrix by P-15 peptide for the promotion of early bone formation.
    Biomaterials, 26(28): 5648-57. [Abstract] [Full-text]
83. Effect of resistance exercise on skeletal muscle myopathy in heart transplant recipients.
    Am J Cardiol, 95(10): 1192-8. [Abstract] [Full-text]
84. Chronic allograft nephropathy and nephrotic range proteinuria.
    Clin Transplant, 19(3): 413-7. [Abstract] [Full-text]
85. United Network for Organ Sharing's expanded criteria donors: is stratification useful?
    Clin Transplant, 19(3): 406-12. [Abstract] [Full-text]
86. Outcome of hepatic artery reconstruction in liver transplantation with an iliac arterial interposition graft.
    Clin Transplant, 19(3): 399-405. [Abstract] [Full-text]
87. Risk factors for delayed kidney function and impact of delayed function on patient and graft survival in adult graft recipients.
    Clin Transplant, 19(3): 391-8. [Abstract] [Full-text]
88. Expanding the donor pool: use of renal transplants from non-heart-beating donors supported with extracorporeal membrane oxygenation.
    Clin Transplant, 19(3): 383-90. [Abstract] [Full-text]
89. Pulmonary infections increase exhaled nitric oxide in lung transplant recipients: a longitudinal study.
    Clin Transplant, 19(3): 377-82. [Abstract] [Full-text]
90. Negative impact of 'old-to-old' donations on success of cadaveric renal transplants.
    Clin Transplant, 19(3): 372-6. [Abstract] [Full-text]
91. Blood glutathione as a marker of cardiac allograft vasculopathy in heart transplant recipients.
    Clin Transplant, 19(3): 367-71. [Abstract] [Full-text]
92. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation.
    Clin Transplant, 19(3): 364-6. [Abstract] [Full-text]
93. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Clin Transplant, 19(3): 357-63. [Abstract] [Full-text]
94. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Clin Transplant, 19(3): 340-5. [Abstract] [Full-text]
95. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.
    Clin Transplant, 19(3): 335-9. [Abstract] [Full-text]
96. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
    Clin Transplant, 19(3): 327-34. [Abstract] [Full-text]
97. Outcome of renal transplants from pediatric donors <5 yr of age.
    Clin Transplant, 19(3): 316-20. [Abstract] [Full-text]
98. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial.
    Clin Transplant, 19(3): 309-15. [Abstract] [Full-text]
99. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule.
    Clin Transplant, 19(3): 304-8. [Abstract] [Full-text]
100. The use of low dose octreotide prophylaxis in pancreatic transplants with enteric drainage. Results of a prospective randomized single center trial.
     Clin Transplant, 19(3): 299-303. [Abstract] [Full-text]
101. Guidelines for the treatment and management of new-onset diabetes after transplantation.
     Clin Transplant, 19(3): 291-8. [Abstract] [Full-text]
102. The evaluation of processed cancellous bovine bone as a bone graft substitute.
     Clin Oral Implants Res, 16(3): 379-86. [Abstract] [Full-text]
103. Does platelet-rich plasma promote remodeling of autologous bone grafts used for augmentation of the maxillary sinus floor?
     Clin Oral Implants Res, 16(3): 349-56. [Abstract] [Full-text]
104. Polyomavirus nephropathy after renal transplantation: a single centre experience.
     Nephrology (Carlton), 10(2): 198-203. [Abstract] [Full-text]
105. Major depression and the use of electroconvulsive therapy (ECT) in lung transplant recipients.
     Psychosomatics, 46(3): 244-9. [Abstract] [Full-text]
106. Routine insertion of ureteral stent in live-donor renal transplantation: is it worthwhile?
     Urology, 65(5): 867-71. [Abstract] [Full-text]
107. Laparoscopic live donor nephrectomy has equivalent early and late renal function outcomes compared with open donor nephrectomy.
     Urology, 65(5): 862-6. [Abstract] [Full-text]
108. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.
     Kidney Int, 67(6): 2454-61. [Abstract] [Full-text]
109. Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France.
     Kidney Int, 67(6): 2448-53. [Abstract] [Full-text]
110. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.
     Kidney Int, 67(6): 2440-7. [Abstract] [Full-text]
111. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.
     Kidney Int, 67(6): 2415-21. [Abstract] [Full-text]
112. The advanced age deceased kidney donor: current outcomes and future opportunities.
     Kidney Int, 67(6): 2407-14. [Abstract] [Full-text]
113. The effect of a first kidney transplant on a subsequent transplant outcome: an experimental and clinical study.
     Kidney Int, 67(6): 2368-75. [Abstract] [Full-text]
114. Periodontal healing in one-wall intra-bony defects in dogs following implantation of autogenous bone or a coral-derived biomaterial.
     J Clin Periodontol, 32(6): 583-9. [Abstract] [Full-text]
115. Detection of chronic rejection by quantitative ventilation scintigrams in lung-transplanted patients: a pilot study.
     Clin Physiol Funct Imaging, 25(3): 183-7. [Abstract] [Full-text]
116. Campath-1H use in pediatric renal transplantation.
     Am J Transplant, 5(6): 1569-73. [Abstract] [Full-text]
117. BK virus associated nephropathy in native kidneys of a heart allograft recipient.
     Am J Transplant, 5(6): 1562-8. [Abstract] [Full-text]
118. Extended survival by urgent liver retransplantation after using a first graft with metastasis from initially unrecognized donor sarcoma.
     Am J Transplant, 5(6): 1559-61. [Abstract] [Full-text]
119. The economic implications of noninvasive molecular testing for cardiac allograft rejection.
     Am J Transplant, 5(6): 1553-8. [Abstract] [Full-text]
120. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans.
     Am J Transplant, 5(6): 1548-52. [Abstract] [Full-text]
121. Heparin-induced thrombocytopenia in a renal transplant recipient.
     Am J Transplant, 5(6): 1537-40. [Abstract] [Full-text]
122. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis.
     Am J Transplant, 5(6): 1529-36. [Abstract] [Full-text]
123. Pre-donation assessment of kidneys by magnetic resonance angiography and venography: accuracy and impact on outcomes.
     Am J Transplant, 5(6): 1518-28. [Abstract] [Full-text]
124. En-bloc kidney transplantation in the United states: an analysis of united network of organ sharing (UNOS) data from 1987 to 2003.
     Am J Transplant, 5(6): 1513-7. [Abstract] [Full-text]
125. Preferences, knowledge, communication and patient-physician discussion of living kidney transplantation in African American families.
     Am J Transplant, 5(6): 1503-12. [Abstract] [Full-text]
126. Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts.
     Am J Transplant, 5(6): 1490-4. [Abstract] [Full-text]
127. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation.
     Am J Transplant, 5(6): 1483-9. [Abstract] [Full-text]
128. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.
     Am J Transplant, 5(6): 1477-82. [Abstract] [Full-text]
129. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality.
     Am J Transplant, 5(6): 1469-76. [Abstract] [Full-text]
130. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
     Am J Transplant, 5(6): 1462-8. [Abstract] [Full-text]
131. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.
     Am J Transplant, 5(6): 1452-61. [Abstract] [Full-text]
132. Everolimus alters the bronchoalveolar lavage and endobronchial biopsy immunologic profile post-human lung transplantation.
     Am J Transplant, 5(6): 1446-51. [Abstract] [Full-text]
133. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.
     Am J Transplant, 5(6): 1423-9. [Abstract] [Full-text]
134. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells.
     Am J Transplant, 5(6): 1415-22. [Abstract] [Full-text]
135. Long-term deterioration of kidney allograft function.
     Am J Transplant, 5(6): 1405-14. [Abstract] [Full-text]
136. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation.
     Am J Transplant, 5(6): 1397-404. [Abstract] [Full-text]
137. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus.
     Am J Transplant, 5(6): 1392-6. [Abstract] [Full-text]
138. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
     Am J Transplant, 5(6): 1383-91. [Abstract] [Full-text]
139. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney.
     Am J Transplant, 5(6): 1375-82. [Abstract] [Full-text]
140. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis.
     Am J Transplant, 5(6): 1367-74. [Abstract] [Full-text]
141. Association between mannose-binding lectin levels and graft survival in kidney transplantation.
     Am J Transplant, 5(6): 1361-6. [Abstract] [Full-text]
142. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center.
     Am J Transplant, 5(6): 1354-60. [Abstract] [Full-text]
143. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
     Am J Transplant, 5(6): 1347-53. [Abstract] [Full-text]
144. Impact of right lobe with middle hepatic vein graft in living-donor liver transplantation.
     Am J Transplant, 5(6): 1339-46. [Abstract] [Full-text]
145. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation.
     Am J Transplant, 5(6): 1332-8. [Abstract] [Full-text]
146. Attitudes toward transplantation in U.K. Muslim Indo-Asians in west London.
     Am J Transplant, 5(6): 1326-31. [Abstract] [Full-text]
147. Determinants of transplant surgeons' willingness to provide organs to patients infected with HBV, HCV or HIV.
     Am J Transplant, 5(6): 1319-25. [Abstract] [Full-text]
148. Laparoscopic procurement of kidneys with multiple renal arteries is associated with increased ureteral complications in the recipient.
     Am J Transplant, 5(6): 1312-8. [Abstract] [Full-text]
149. MDRD equations for estimation of GFR in renal transplant recipients.
     Am J Transplant, 5(6): 1306-11. [Abstract] [Full-text]
150. Progression of alloresponse and tissue-specific immunity during graft coronary artery disease.
     Am J Transplant, 5(6): 1286-96. [Abstract] [Full-text]
151. Acute rejection after rat renal transplantation leads to downregulation of NA+ and water channels in the collecting duct.
     Am J Transplant, 5(6): 1276-85. [Abstract] [Full-text]
152. The influence of phosphatidylinositol 3-kinase/Akt pathway on the ischemic injury during rat liver graft preservation.
     Am J Transplant, 5(6): 1264-75. [Abstract] [Full-text]
153. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.
     Am J Transplant, 5(6): 1256-63. [Abstract] [Full-text]
154. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries.
     Am J Transplant, 5(6): 1226-36. [Abstract] [Full-text]
155. In vivo molecular imaging characterizes pulmonary gene expression during experimental lung transplantation.
     Am J Transplant, 5(6): 1216-25. [Abstract] [Full-text]
156. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis.
     Am J Transplant, 5(6): 1179-85. [Abstract] [Full-text]
157. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection. Clinicopathologic correlations during the first 6 months after lung transplantation.
     Hum Pathol, 36(4): 387-94. [Abstract] [Full-text]
158. MR imaging of avascular scaphoid nonunion before and after vascularized bone grafting.
     Skeletal Radiol, 34(6): 314-20. [Abstract] [Full-text]
159. Left atrial myxoma in transplanted heart.
     Heart, 91(6): e49. [Abstract] [Full-text]
160. Ultrasonic strain/strain rate imaging--a new clinical tool to evaluate the transplanted heart.
     Eur J Echocardiogr, 6(3): 186-95. [Abstract] [Full-text]
161. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft.
     Immunol Lett, 99(1): 30-5. [Abstract] [Full-text]
162. Origin of regenerated axons in nerve bypass grafts.
     J Neurotrauma, 22(5): 605-12. [Abstract] [Full-text]
163. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.
     Nephrol Dial Transplant, 20(6): 1214-21. [Abstract] [Full-text]
164. Survival after pediatric liver transplantation: why does living donation offer an advantage?
     Arch Surg, 140(5): 465-70; discussion 470-1. [Abstract] [Full-text]
165. Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease.
     Arch Surg, 140(5): 459-64; discussion 464. [Abstract] [Full-text]
166. Vascularised free fibular flap in bone resection and reconstruction.
     Br J Plast Surg, 58(4): 425-30. [Abstract] [Full-text]
167. Ascending aortic aneurysm after pediatric heart transplantation: case report of an unusual complication.
     J Heart Lung Transplant, 24(5): 638-41. [Abstract] [Full-text]
168. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation.
     J Heart Lung Transplant, 24(5): 635-7. [Abstract] [Full-text]
169. Use of rituximab to decrease panel-reactive antibodies.
     J Heart Lung Transplant, 24(5): 628-30. [Abstract] [Full-text]
170. Pulmonary embolization of microcrystalline cellulose in a lung transplant recipient.
     J Heart Lung Transplant, 24(5): 624-7. [Abstract] [Full-text]
171. West Nile virus encephalitis infection in a heart transplant recipient: a case report.
     J Heart Lung Transplant, 24(5): 621-3. [Abstract] [Full-text]
172. End-stage cardiac failure caused by isolated ventricular non-compaction: cardiac transplantation in a 5-year-old boy.
     J Heart Lung Transplant, 24(5): 618-20. [Abstract] [Full-text]
173. Blood transfers infectious immunologic tolerance in MHC-incompatible heart transplantation in rats.
     J Heart Lung Transplant, 24(5): 614-7. [Abstract] [Full-text]
174. Long-term preservation using a new apparatus combined with suppression of pro-inflammatory cytokines improves donor heart function after transplantation in a canine model.
     J Heart Lung Transplant, 24(5): 602-8. [Abstract] [Full-text]
175. Endothelial activation in the transplanted human heart from organ retrieval to 3 months after transplantation: an observational study.
     J Heart Lung Transplant, 24(5): 593-601. [Abstract] [Full-text]
176. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study.
     J Heart Lung Transplant, 24(5): 588-92. [Abstract] [Full-text]
177. Extended ganciclovir prophylaxis in lung transplantation.
     J Heart Lung Transplant, 24(5): 583-7. [Abstract] [Full-text]
178. Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation: a multicenter study.
     J Heart Lung Transplant, 24(5): 576-82. [Abstract] [Full-text]
179. Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy?
     J Heart Lung Transplant, 24(5): 559-65. [Abstract] [Full-text]
180. Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy.
     J Heart Lung Transplant, 24(5): 551-8. [Abstract] [Full-text]
181. Diagnostic and prognostic value of dobutamine thallium-201 single-photon emission computed tomography after heart transplantation.
     J Heart Lung Transplant, 24(5): 544-50. [Abstract] [Full-text]
182. Effects of inhaled FK 506 on the suppression of acute rejection after lung transplantation: use of a rat orthotopic lung transplantation model.
     J Heart Lung Transplant, 24(5): 538-43. [Abstract] [Full-text]
183. A descriptive study of small airway reticular basement membrane thickening in clinically stable lung transplant recipients.
     J Heart Lung Transplant, 24(5): 533-7. [Abstract] [Full-text]
184. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation.
     J Heart Lung Transplant, 24(5): 526-32. [Abstract] [Full-text]
185. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.
     J Heart Lung Transplant, 24(5): 517-25. [Abstract] [Full-text]
186. Synergistic effect of low dose cyclosporine A and human interleukin 10 overexpression on acute rejection in rat lung allotransplantation.
     Eur J Cardiothorac Surg, 27(6): 1030-5. [Abstract] [Full-text]
187. Cumulative risk adjusted monitoring of 30-day mortality after cardiothoracic transplantation: UK experience.
     Eur J Cardiothorac Surg, 27(6): 1022-9. [Abstract] [Full-text]
188. A case of suspected severe pulmonary embolism in a living-related liver transplantation donor.
     J Clin Anesth, 17(3): 218-20. [Abstract] [Full-text]
189. Systemic vasodilation is a predominant cause of hypotension in a patient with familial amyloid polyneuropathy during liver transplantation.
     J Clin Anesth, 17(3): 202-4. [Abstract] [Full-text]
190. A new incision design for mandibular symphysis bone-grafting procedures.
     J Periodontol, 76(5): 845-9. [Abstract] [Full-text]
191. Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation.
     J Clin Pharmacol, 45(6): 666-73. [Abstract] [Full-text]
192. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
     J Clin Virol, 33(2): 138-44. [Abstract] [Full-text]
193. Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States.
     Liver Int, 25(3): 536-41. [Abstract] [Full-text]
194. Biological and psychological differences in the child and adolescent transplant recipient.
     Pediatr Transplant, 9(3): 416-21. [Abstract] [Full-text]
195. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint.
     Pediatr Transplant, 9(3): 398-407. [Abstract] [Full-text]
196. Replacing calcineurin inhibitors with mTOR inhibitors in children.
     Pediatr Transplant, 9(3): 391-7. [Abstract] [Full-text]
197. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients.
     Pediatr Transplant, 9(3): 381-90. [Abstract] [Full-text]
198. Growing up and moving on: transition from pediatric to adult care.
     Pediatr Transplant, 9(3): 364-72. [Abstract] [Full-text]
199. Gynecologic health care for the adolescent solid organ transplant recipient.
     Pediatr Transplant, 9(3): 346-56. [Abstract] [Full-text]
200. Transfusion requirements during cadaveric and living donor pediatric liver transplantation.
     Pediatr Transplant, 9(3): 332-7. [Abstract] [Full-text]
201. C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?
     Pediatr Transplant, 9(3): 328-31. [Abstract] [Full-text]
202. Recurrent urinary tract infection in the post-transplant reflux nephropathy patient: is reflux in the native ureter the culprit?
     Pediatr Transplant, 9(3): 324-7. [Abstract] [Full-text]
203. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.
     Pediatr Transplant, 9(3): 315-23. [Abstract] [Full-text]
204. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.
     Pediatr Transplant, 9(3): 299-304. [Abstract] [Full-text]
205. Hepatic venous reconstruction in pediatric living-related donor liver transplantation--experience of a single center.
     Pediatr Transplant, 9(3): 293-8. [Abstract] [Full-text]
206. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
     Pediatr Transplant, 9(3): 282-92. [Abstract] [Full-text]
207. Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats.
     Transpl Int, 18(6): 743-9. [Abstract] [Full-text]
208. Successful outcome following transplantation of an injured liver from a nonheart beating donor.
     Transpl Int, 18(6): 724-6. [Abstract] [Full-text]
209. Intraperitoneal catheter drainage of lymphocele: an outpatient procedure.
     Transpl Int, 18(6): 721-3. [Abstract] [Full-text]
210. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier.
     Transpl Int, 18(6): 716-20. [Abstract] [Full-text]
211. Older liver graft transplantation, cholestasis and synthetic graft function.
     Transpl Int, 18(6): 709-15. [Abstract] [Full-text]
212. Cardiac hepatopathy before and after heart transplantation.
     Transpl Int, 18(6): 697-702. [Abstract] [Full-text]
213. Severe endocarditis in transplant recipients--an epidemiologic study.
     Transpl Int, 18(6): 690-6. [Abstract] [Full-text]
214. Impact of cytokine gene polymorphism on cardiovascular risk in renal transplant recipients.
     Transpl Int, 18(6): 681-9. [Abstract] [Full-text]
215. Role of CXCR3 in cellular but not humoral renal allograft rejection.
     Transpl Int, 18(6): 676-80. [Abstract] [Full-text]
216. Liver transplantation in patients with hepatic hydrothorax.
     Transpl Int, 18(6): 672-5. [Abstract] [Full-text]
217. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients.
     Transpl Int, 18(6): 668-71. [Abstract] [Full-text]
218. Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia.
     Transpl Int, 18(6): 664-7. [Abstract] [Full-text]
219. Living-related liver transplantation for Wilson's disease.
     Transpl Int, 18(6): 651-6. [Abstract] [Full-text]
220. Gastrointestinal complications in renal transplant recipients.
     Transpl Int, 18(6): 643-50. [Abstract] [Full-text]
221. Bile duct complications after liver transplantation.
     Transpl Int, 18(6): 627-42. [Abstract] [Full-text]
222. Identification and characterization of two genes (MIP-1beta, VE-CADHERIN) implicated in acute rejection in human heart transplantation: use of murine models in tandem with cDNA arrays.
     Circulation, 111(20): 2636-44. [Abstract] [Full-text]
223. Alternative EBNA1 expression in organ transplant patients.
     J Med Virol, 76(3): 378-85. [Abstract] [Full-text]
224. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
     J Med Virol, 76(3): 367-72. [Abstract] [Full-text]
225. Percutaneous transhepatic balloon dilation of portal venous stenosis in patients with living donor liver transplantation.
     Radiology, 235(3): 1078-83. [Abstract] [Full-text]
226. Multi-detector row CT in evaluation of 94 living renal donors by readers with varied experience.
     Radiology, 235(3): 905-10. [Abstract] [Full-text]
227. Living donor candidates for right hepatic lobe transplantation: evaluation at CT cholangiography--initial experience.
     Radiology, 235(3): 899-904. [Abstract] [Full-text]
228. The effect of primary graft dysfunction on survival after lung transplantation.
     Am J Respir Crit Care Med, 171(11): 1312-6. [Abstract] [Full-text]
229. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
     Braz J Med Biol Res, 38(5): 683-94. [Abstract] [Full-text]
230. Is there any difference in anesthetic management of biliary atresia and glycogen storage disease patients undergoing liver transplantation?
     J Surg Res, 126(1): 82-5. [Abstract] [Full-text]
231. Endometrial adenocarcinoma after liver transplantation.
     J Obstet Gynaecol Res, 31(3): 224-6. [Abstract] [Full-text]
232. Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325.
     J Am Soc Nephrol, 16(6): 1752-7. [Abstract] [Full-text]
233. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG).
     J Am Soc Nephrol, 16(6): 1849-58. [Abstract] [Full-text]
234. Impact of cadaveric renal transplantation on survival in patients listed for transplantation.
     J Am Soc Nephrol, 16(6): 1859-65. [Abstract] [Full-text]
235. Viral infection in the renal transplant recipient.
     J Am Soc Nephrol, 16(6): 1758-74. [Abstract] [Full-text]
236. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation.
     J Am Soc Nephrol, 16(6): 1839-48. [Abstract] [Full-text]
237. Hepatic nodules in liver transplantation candidates: MR imaging and underlying hepatic disease.
     Magn Reson Imaging, 23(4): 557-62. [Abstract] [Full-text]
238. Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles.
     Transplant Proc, 37(4): 1962-4. [Abstract] [Full-text]
239. Identification of early tolerance regulator genes induced by allochimeric therapy using microarray-based genomewide scan.
     Transplant Proc, 37(4): 1942-3. [Abstract] [Full-text]
240. Effects of noninherited maternal antigens on allotransplant rejection in a transgenic mouse model.
     Transplant Proc, 37(4): 1940-1. [Abstract] [Full-text]
241. Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats.
     Transplant Proc, 37(4): 1926-8. [Abstract] [Full-text]
242. Use of echocardiography to assess function of hDAF-transgenic pig cardiac xenografts.
     Transplant Proc, 37(4): 1923-5. [Abstract] [Full-text]
243. Severe hearing loss after liver transplantation.
     Transplant Proc, 37(4): 1918-9. [Abstract] [Full-text]
244. Gonadal function and immunosuppressive therapy after renal transplantation.
     Transplant Proc, 37(4): 1915-7. [Abstract] [Full-text]
245. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
     Transplant Proc, 37(4): 1912-4. [Abstract] [Full-text]
246. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic.
     Transplant Proc, 37(4): 1910-1. [Abstract] [Full-text]
247. Kaposi sarcoma in solid organ transplant recipients: a single center report.
     Transplant Proc, 37(4): 1905-9. [Abstract] [Full-text]
248. No increase in rejection or graft loss in kidney transplant recipients with thrombophilia treated with anticoagulation and triple immunosuppression.
     Transplant Proc, 37(4): 1902-4. [Abstract] [Full-text]
249. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
     Transplant Proc, 37(4): 1900-1. [Abstract] [Full-text]
250. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study.
     Transplant Proc, 37(4): 1898-9. [Abstract] [Full-text]
251. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression.
     Transplant Proc, 37(4): 1896-7. [Abstract] [Full-text]
252. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
     Transplant Proc, 37(4): 1889-91. [Abstract] [Full-text]
253. Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppresion.
     Transplant Proc, 37(4): 1885-8. [Abstract] [Full-text]
254. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile.
     Transplant Proc, 37(4): 1877-9. [Abstract] [Full-text]
255. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
     Transplant Proc, 37(4): 1874-6. [Abstract] [Full-text]
256. Cardiovascular risk estimates and risk factors in renal transplant recipients.
     Transplant Proc, 37(4): 1868-70. [Abstract] [Full-text]
257. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
     Transplant Proc, 37(4): 1865-7. [Abstract] [Full-text]
258. No influence of immunosuppression on insulin sensitivity and beta-cell function in living donor liver transplantation.
     Transplant Proc, 37(4): 1861-4. [Abstract] [Full-text]
259. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation.
     Transplant Proc, 37(4): 1857-60. [Abstract] [Full-text]
260. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience.
     Transplant Proc, 37(4): 1851-6. [Abstract] [Full-text]
261. Successful management of recurrent Epstein-Barr virus-associated multilocular leiomyosarcoma after cardiac transplantation.
     Transplant Proc, 37(4): 1839-44. [Abstract] [Full-text]
262. Preservation of renal function after heart transplantation: initial single-center experience with sirolimus.
     Transplant Proc, 37(4): 1835-8. [Abstract] [Full-text]
263. Impact of steroid withdrawal on metabolic parameters in a series of 112 enteric/systemic-drained pancreatic transplants.
     Transplant Proc, 37(4): 1821-5. [Abstract] [Full-text]
264. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
     Transplant Proc, 37(4): 1818-20. [Abstract] [Full-text]
265. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
     Transplant Proc, 37(4): 1815-7. [Abstract] [Full-text]
266. Splenic radiation and double-filtration plasmapheresis in crossmatch-positive live renal transplantation.
     Transplant Proc, 37(4): 1806-7. [Abstract] [Full-text]
267. Improved graft survival in ABO-incompatible living donor kidney transplantation.
     Transplant Proc, 37(4): 1804-5. [Abstract] [Full-text]
268. Successful results after 5 years of tacrolimus therapy in ABO-incompatible kidney transplantation in Japan.
     Transplant Proc, 37(4): 1800-3. [Abstract] [Full-text]
269. The cost of steroid-free protocols in primary cadaver kidney transplantation.
     Transplant Proc, 37(4): 1797-9. [Abstract] [Full-text]
270. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe.
     Transplant Proc, 37(4): 1795-6. [Abstract] [Full-text]
271. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results.
     Transplant Proc, 37(4): 1792-4. [Abstract] [Full-text]
272. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
     Transplant Proc, 37(4): 1789-91. [Abstract] [Full-text]
273. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
     Transplant Proc, 37(4): 1785-8. [Abstract] [Full-text]
274. Prognosis of HTLV-I-positive renal transplant recipients.
     Transplant Proc, 37(4): 1779-82. [Abstract] [Full-text]
275. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
     Transplant Proc, 37(4): 1776-8. [Abstract] [Full-text]
276. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial.
     Transplant Proc, 37(4): 1774-5. [Abstract] [Full-text]
277. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors.
     Transplant Proc, 37(4): 1771-3. [Abstract] [Full-text]
278. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan.
     Transplant Proc, 37(4): 1769-70. [Abstract] [Full-text]
279. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan.
     Transplant Proc, 37(4): 1767-8. [Abstract] [Full-text]
280. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients.
     Transplant Proc, 37(4): 1764-6. [Abstract] [Full-text]
281. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression.
     Transplant Proc, 37(4): 1760-1. [Abstract] [Full-text]
282. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.
     Transplant Proc, 37(4): 1757-9. [Abstract] [Full-text]
283. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
     Transplant Proc, 37(4): 1751-3. [Abstract] [Full-text]
284. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function.
     Transplant Proc, 37(4): 1748-50. [Abstract] [Full-text]
285. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
     Transplant Proc, 37(4): 1745-7. [Abstract] [Full-text]
286. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters.
     Transplant Proc, 37(4): 1741-4. [Abstract] [Full-text]
287. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
     Transplant Proc, 37(4): 1736-8. [Abstract] [Full-text]
288. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay.
     Transplant Proc, 37(4): 1733-5. [Abstract] [Full-text]
289. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
     Transplant Proc, 37(4): 1730-2. [Abstract] [Full-text]
290. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
     Transplant Proc, 37(4): 1728-9. [Abstract] [Full-text]
291. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
     Transplant Proc, 37(4): 1725-7. [Abstract] [Full-text]
292. Immunosuppression withdrawal after auxiliary liver transplantation for acute liver failure.
     Transplant Proc, 37(4): 1720-1. [Abstract] [Full-text]
293. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen.
     Transplant Proc, 37(4): 1718-9. [Abstract] [Full-text]
294. The influence of late acute rejection episodes on long-term graft outcome after liver transplantation.
     Transplant Proc, 37(4): 1716-7. [Abstract] [Full-text]
295. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation.
     Transplant Proc, 37(4): 1713-5. [Abstract] [Full-text]
296. Influence of methicillin-resistant Staphylococcus aureus carrier status in liver transplant recipients.
     Transplant Proc, 37(4): 1710-2. [Abstract] [Full-text]
297. Long-term outcome of immunosuppression withdrawal after liver transplantation.
     Transplant Proc, 37(4): 1708-9. [Abstract] [Full-text]
298. Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
     Transplant Proc, 37(4): 1705-7. [Abstract] [Full-text]
299. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation.
     Transplant Proc, 37(4): 1703-4. [Abstract] [Full-text]
300. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
     Transplant Proc, 37(4): 1700-2. [Abstract] [Full-text]
301. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
     Transplant Proc, 37(4): 1697-9. [Abstract] [Full-text]
302. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis.
     Transplant Proc, 37(4): 1695-6. [Abstract] [Full-text]
303. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
     Transplant Proc, 37(4): 1691-2. [Abstract] [Full-text]
304. Blockade of fibronectin-alpha4beta1 adhesive interactions down-regulates cyclooxygenase-2 inducible nitric oxide synthase and prolongs recipient survival in a 24-hour model of cold hepatic ischemia-reperfusion injury.
     Transplant Proc, 37(4): 1682-3. [Abstract] [Full-text]
305. Ischemia and reperfusion injury in liver transplantation.
     Transplant Proc, 37(4): 1653-6. [Abstract] [Full-text]
306. A model for scoring and grading willingness of a potential living related donor.
     J Med Ethics, 31(6): 338-40. [Abstract] [Full-text]
307. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
     Clin Ther, 27(4): 463-9. [Abstract] [Full-text]
308. Cryopreserved iliac artery is indispensable interposition graft material for middle hepatic vein reconstruction of right liver grafts.
     Liver Transpl, 11(6): 644-9. [Abstract] [Full-text]
309. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
     Liver Transpl, 11(6): 700-4. [Abstract] [Full-text]
310. Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non-heart beating donor.
     Liver Transpl, 11(6): 696-9. [Abstract] [Full-text]
311. Dynamic left ventricular outflow tract obstruction in an orthotopic liver transplant recipient.
     Liver Transpl, 11(6): 692-5. [Abstract] [Full-text]
312. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension.
     Liver Transpl, 11(6): 627-34; discussion 610-1. [Abstract] [Full-text]
313. Intraoperative direct measurement of hepatic arterial buffer response in patients with or without cirrhosis.
     Liver Transpl, 11(6): 684-91. [Abstract] [Full-text]
314. Liver transplant recipient selection: MELD vs. clinical judgment.
     Liver Transpl, 11(6): 621-6. [Abstract] [Full-text]
315. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem.
     Liver Transpl, 11(6): 679-83. [Abstract] [Full-text]
316. Impact of donor gender on male rat recipients of small-for-size liver grafts.
     Liver Transpl, 11(6): 669-78. [Abstract] [Full-text]
317. New-onset diabetes after liver transplantation: from pathogenesis to management.
     Liver Transpl, 11(6): 612-20. [Abstract] [Full-text]
318. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
     Liver Transpl, 11(6): 656-62. [Abstract] [Full-text]
319. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.
     Hepatology, 41(6): 1282-9. [Abstract] [Full-text]
320. Heart transplantation and consecutive mitral valve replacement.
     Thorac Cardiovasc Surg, 53(3): 178-80. [Abstract] [Full-text]
321. Islet transplantation: progress and challenge.
     Arch Med Res, 36(3): 273-80. [Abstract] [Full-text]
322. Obliterative airway disease in rat tracheal allografts requires tumor necrosis factor alpha.
     Exp Mol Pathol, 78(3): 190-7. [Abstract] [Full-text]
323. The role of CC and CXC chemokines in cardiac allograft rejection in rats.
     Exp Mol Pathol, 78(3): 171-6. [Abstract] [Full-text]
324. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants.
     Br J Surg, 92(6): 681-7. [Abstract] [Full-text]

© 2004-2011 Organ Transplantation Research Today. All Rights Reserved.